Condition: Fabry Disease · Sponsor: Amicus Therapeutics
This is a global prospective observational study of women with Fabry disease and their infants during pregnancy and/or breastfeeding. The study will evaluate outcomes of pregnancy and/or breastfeeding in women and infants exposed to migalastat.
This description comes directly from the study's public registry record.
Pregnancy Registry Call Center · 888-239-0758 · galafoldpregnancy@ubc.com
Always discuss trial participation with your own doctor first.
| Amicus Therapeutics, Inc. Pregnancy Registry | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04252066